Biotech

All Articles

Kairos goes social along with $6M IPO to fund tests of cancer cells drug

.With a triad of biotechs attacking the Nasdaq on Friday, it was very easy to miss a smaller-scale p...

Vaccine and Keytruda combo helpful in squamous tissue cancer

.Invulnerable gate inhibitors are the superheroes of cancer cells treatment. Medicines like Bristol ...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of substantial management hirings, shootings ...

Regeneron's Opdualag rival reveals 57% reaction cost

.Regeneron is back with long-lasting consequence for its own LAG-3 inhibitor as well as PD-1 inhibit...

AstraZeneca articles data on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early examine the performance of its in-house antibody-dr...

iTeos- GSK's TIGIT celebrity reveals significant renovation

.After declaring a period 3 launch based on good midstage results, iTeos and GSK are lastly discussi...

More collaborative FDA can speed up unusual ailment R&ampD: record

.The FDA must be a lot more open as well as collective to release a rise in commendations of rare co...

Zenas, MBX, Bicara head to Nasdaq in hot day for biotech IPOs

.It's an abnormally active Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara Thera...

Atea's COVID antiviral falls short to halt hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has actually fallen short yet another COVID-19 trial, however the b...

Neurocrine's offer to save schizophrenia prospect fails

.Neurocrine Biosciences' mental illness plan pivot has fallen short. The biotech was actually unable...